# LyncBio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lyncbio-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.lyncbio.com
- Latest round: Series A (May 18, 2026)
- Investors on record: 5

## About

Based in Shanghai, China and founded in 2023, Lingtai Tianrun Biotechnology (Shanghai) Co., Ltd., dba LyncBio Therapeutics, is a biotechnology company specializing in developing innovative Antibody-Drug Conjugates (ADCs) aimed at improving targeted cancer therapies.

In May 2026, LyncBio Therapeutics closed a round of series A+ funding from Apricot Capital.

LyncBio Therapeutics specializes in the development and innovation of next-generation Antibody-Drug Conjugates (ADCs), designed to enhance targeted cancer therapies. Their offerings include a suite of multifunctional carriers, conjugates, linkers, and drug payloads, enabling precise targeting of cancer cells via single-target and dual-target ADC designs. The company utilizes advanced methodologies and proprietary technology platforms to address global patient needs in oncology, inflammatory bowel disease, and multiple sclerosis, aiming for broad international market reach.

LyncBio generates revenue through strategic partnerships and collaborations with healthcare providers and research institutions seeking advanced therapeutic solutions.

## Funding rounds

- Series A, May 18, 2026 — Apricot Capital
- Series A, Mar 29, 2026 — BioTrack Capital
- Seed, Nov 16, 2023 — Legend Star, Apricot Capital, Shileng Investment, Elikon Venture

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Seed
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Seed, Series A
- Shileng Investment (https://capitalatlas.ai/funds/shileng-investment) — Seed
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Seed
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A